Vendor review
Xingtai Jiachuang Technology reviews
Xingtai Jiachuang Technology reviews from 68 independent lab tests (Tirzepatide, Retatrutide and Tesamorelin): grade A, purity and fill accuracy. Is Xingtai Jiachuang Technology legit? See what its vials showed.
What the lab tests show
68 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Sep 16, 2026 | Retatrutide | 100 % | 11.5339 mg of 10 mg (15 %) | Pass | View |
| Sep 16, 2026 | Tirzepatide | 99.9 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Sep 15, 2026 | GHK-Cu | 99.9 % | 53.1 mg of 50 mg (6 %) | Pass | View |
| Aug 26, 2026 | Retatrutide | 98.8 % | 8.14 mg of 10 mg (-19 %) | Pass | View |
| Aug 15, 2026 | Retatrutide | 99.8 % | 9.8 mg of 10 mg (-2 %) | Pass | View |
| Aug 3, 2026 | GHK-Cu | 99.9 % | 64.6 mg of 100 mg (-35 %) | Pass | View |
| Jul 20, 2026 | Tirzepatide | 99.8 % | 27.4 mg of 30 mg (-9 %) | Pass | View |
| Jul 20, 2026 | GHK-Cu | 99.9 % | 90.6 mg of 100 mg (-9 %) | Pass | View |
| Jul 20, 2026 | GHK-Cu | 99.5 % | 106.4 mg of 100 mg (6 %) | Pass | View |
| Jul 13, 2026 | Retatrutide | 5 mg | Fail | View | |
| Jul 13, 2026 | Retatrutide | 10 mg | Fail | View | |
| Jul 13, 2026 | Retatrutide | 10 mg | Fail | View | |
| Jul 13, 2026 | Tirzepatide | 99.8 % | 35 mg of 30 mg (17 %) | Pass | View |
| Jul 13, 2026 | Tirzepatide | 15 mg | Fail | View | |
| Jul 13, 2026 | Tesamorelin | 10 mg | Fail | View | |
| Jun 22, 2026 | Tirzepatide | 99.9 % | 28.5 mg of 30 mg (-5 %) | Pass | View |
| Jun 17, 2026 | Retatrutide | 99.7 % | 9.8 mg of 10 mg (-2 %) | Pass | View |
| Jun 17, 2026 | Tesamorelin | 99.3 % | 2.4 mg of 10 mg (-76 %) | Pass | View |
| Jun 16, 2026 | Retatrutide | 99.9 % | 4.68 mg of 5 mg (-6 %) | Pass | View |
| Jun 16, 2026 | GHK-Cu | 99.9 % | 41.5 mg of 50 mg (-17 %) | Pass | View |
| May 20, 2026 | Tirzepatide | 99.9 % | 20.6 mg of 20 mg (3 %) | Pass | View |
| May 5, 2026 | Tirzepatide | 99.9 % | 9.5 mg of 10 mg (-5 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.6 % | 20.6 mg of 20 mg (3 %) | Pass | View |
| Apr 3, 2026 | Tirzepatide | 99.8 % | 61.8 mg of 60 mg (3 %) | Pass | View |
| Mar 19, 2026 | Retatrutide | 99.9 % | 10 mg of 10 mg (0 %) | Pass | View |
| Mar 13, 2026 | Tirzepatide | 99.8 % | 22 mg of 20 mg (10 %) | Pass | View |
| Mar 10, 2026 | Retatrutide | 99.9 % | 4.32 mg of 5 mg (-14 %) | Pass | View |
| Mar 10, 2026 | Tirzepatide | 98.8 % | 18.7 mg of 15 mg (25 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 60 mg of 60 mg (0 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 39 mg of 60 mg (-35 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.2 % | 12 mg of 10 mg (20 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 31.6 mg of 30 mg (5 %) | Pass | View |
| Mar 4, 2026 | Tirzepatide | 99.89 % | 28.2 mg of 30 mg (-6 %) | Pass | View |
| Mar 2, 2026 | GHK-Cu | 99.9 % | 52.5 mg of 50 mg (5 %) | Pass | View |
| Mar 2, 2026 | BPC-157 | 98.4 % | 9.17 mg of 10 mg (-8 %) | Pass | View |
| Feb 26, 2026 | Tirzepatide | 99.9 % | 5.14 mg of 5 mg (3 %) | Pass | View |
| Feb 25, 2026 | Tirzepatide | 99.9 % | 21 mg of 20 mg (5 %) | Pass | View |
| Feb 20, 2026 | Tesamorelin | 99.06 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.61 % | 15.2 mg of 15 mg (1 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.62 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| Feb 9, 2026 | Tesamorelin | 99.49 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Feb 2, 2026 | Tirzepatide | 98.92 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| Feb 2, 2026 | Tirzepatide | 94.67 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Jan 29, 2026 | Tirzepatide | 99.9 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Jan 29, 2026 | Tirzepatide | 10 mg | Fail | View | |
| Jan 29, 2026 | Tesamorelin | 99.9 % | 9.93 mg of 10 mg (-1 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.8 % | 40.9 mg of 30 mg (36 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.9 % | 19.7 mg of 20 mg (-2 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.8 % | 19.5 mg of 20 mg (-3 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.7 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.8 % | 31.7 mg of 30 mg (6 %) | Pass | View |
| Jan 26, 2026 | Tirzepatide | 99.8 % | 17.7 mg of 20 mg (-12 %) | Pass | View |
| Jan 26, 2026 | Tirzepatide | 99.8 % | 22.7 mg of 20 mg (14 %) | Pass | View |
| Jan 26, 2026 | Tirzepatide | 99.8 % | 37.9 mg of 30 mg (26 %) | Pass | View |
| Jan 19, 2026 | Tesamorelin | 99.95 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| Jan 15, 2026 | Tirzepatide | 99.8 % | 64.1 mg of 60 mg (7 %) | Pass | View |
| Jan 15, 2026 | Tesamorelin | 98.13 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Jan 6, 2026 | GHK-Cu | 99.95 % | 46 mg of 50 mg (-8 %) | Pass | View |
| Jan 6, 2026 | Tesamorelin | 99.95 % | 9.77 mg of 10 mg (-2 %) | Pass | View |
| Jan 6, 2026 | Tesamorelin | 99.32 % | 11.4 mg of 10 mg (14 %) | Pass | View |
What Xingtai Jiachuang Technology sells
No current listings on record.
About Xingtai Jiachuang Technology
Finnrick has tested 68 samples from Xingtai Jiachuang Technology across 5 products.